Share
Journal Information
Most often read
405
“Methodological notes”: a new and important section in Clínica e Investigación en ArteriosclerosisJosep Ribalta, Carlos Lahoz, Xavier Pintó
Clin Investig Arterioscler. 2023;35:243
405
Full text access
Open Article
298
Absence of the influence of the APOE gene on the incidence of type 2 diabetes mellitus in a cohort of workers: Effect of diet and shift workRocío Mateo-Gallego, Sofía Pérez-Calahorra, Ana M. Bea, Irene Gracia-Rubio, Carmen Rodrigo-Carbo, Belen Moreno-Franco, Fernando Civeira, Martín Laclaustra, Itziar Lamiquiz-Moneo
Clin Investig Arterioscler. 2023;35:226-35
298
245
Dietary modulation of advanced glycation end products metabolism on carotid intima-media thickness in type 2 diabetes patients: From the CORDIOPREV studyElena M. Yubero-Serrano, Francisco M. Gutiérrez-Mariscal, Purificación Gómez-Luna, Juan F. Alcalá-Diaz, Pablo Pérez-Martinez, José López-Miranda
Clin Investig Arterioscler. 2023;35:105-14
245
Open Article
229
Clonal hematopoiesis and atherosclerotic cardiovascular disease: A primerMaría A. Zuriaga, José J. Fuster
Clin Investig Arterioscler. 2023;35:35-41
229
Open Article
203
Health-related lifestyle assessment among Spanish adults from 22 to 72 yearsPedro Luis Rodríguez García, Juan José Pérez Soto, Eliseo García Cantó, Marcos Meseguer Zafra, Raúl Salmerón Ríos, Pedro Juan Tárraga López
Clin Investig Arterioscler. 2023;35:12-20
203
Open Article
163
Vascular smooth muscle cell phenotype is modulated by ligands of the lymphotoxin β receptor and the tumor necrosis factor receptorSusana Martín-Vañó, Alejandra Miralles-Abella, Pascual Castaño, Gema Hurtado-Genovés, María Aguilar-Ballester, Andrea Herrero-Cervera, Angela Vinué, Sergio Martínez-Hervás, Herminia González-Navarro
Clin Investig Arterioscler. 2023;35:1-11
163
Full text access
Open Article
155
Vascular smooth muscle cell aging: Insights from Hutchinson-Gilford progeria syndromeMagda R. Hamczyk, Rosa M. Nevado
Clin Investig Arterioscler. 2023;35:42-51
155
Open Article
130
Arterial ageing and atherosclerotic risk: new perspectivesVicente Lahera Juliá, Ana M. Lahera García
Clin Investig Arterioscler. 2023;35:32-4
130
Open Article
117
Prevalence rates of chronic kidney disease and its association with cardiometabolic factors and cardiovascular diseases. SIMETAP-CKD studyAntonio Ruiz-Garcia, Ezequiel Arranz-Martínez, Nerea Iturmendi-Martínez, Teresa Fernández-Vicente, Montserrat Rivera-Teijido, Juan Carlos García-Álvarez
Clin Investig Arterioscler. 2023;35:64-74
117
Open Article
108
Consensus document for lipid profile determination and reporting in Spanish clinical laboratoriesTeresa Arrobas Velilla, Carlos Guijarro, Raquel Campuzano Ruiz, Manuel Rodríguez Piñero, José Francisco Valderrama Marcos, Antonio Pérez Pérez, Manuel Antonio Botana López, Ana Morais López, ... en representación del Grupo Multidisciplinar de Trabajo de Lípidos y Riesgo Vascular
Clin Investig Arterioscler. 2023;35:91-100
108
Full text access
Open Article
101
Geostatistical analysis from the clinical laboratory in cardiovascular prevention for primary careSalomón Martín Pérez, Teresa Arrobas Velilla, Juan Fabiani de la Iglesia, Ignacio Vázquez Rico, Gema Varo Sánchez, Antonio León-Justel
Clin Investig Arterioscler. 2023;35:75-84
101
Open Article
94
Association of rs662799 and rs5070 genetic polymorphisms with hypertriglyceridemia and atherogenic dyslipidemia in pediatric patients in Southeast MexicoValeria Ovando Gómez, Soraya Amalí Zavaleta Muñiz, Héctor Ochoa-Díaz-López, José Armando Camilo Hernández Contreras, Cesar Antonio Irecta Nájera
Clin Investig Arterioscler. 2023;35:53-63
94
Open Article
92
Pemafibrate: PROMINENT failure or an urgent need for therapeutic replacement?Juan Carlos Laguna Egea, Núria Roglans Ribas, Roger Bentanachs Raset
Clin Investig Arterioscler. 2023;35:202-5
92
Full text access
Open Article
89
Eating frequency has an inverse correlation with adiposity measures and non-invasive arterial stiffness parameters in healthy adult peopleSajjad Arefinia, Lida Jarahi, Hamed Khedmatgozar, Saeed Eslami Hasan Abadi, Mohammad Reza Shadmand Foumani Moghadam, André Tchernof, Hosein Soleimaninia, Reza Rezvani
Clin Investig Arterioscler. 2023;35:21-31
89
Open Article
81
Nutrition, cardiovascular disease risk and climate changeCarlos A. González Svatetz
Clin Investig Arterioscler. 2023;35:101-3
81
Full text access
Open Article
78
Observational study of patients from a Lipid Unit on lipid-modifying therapy for primary and secondary prevention: ULFI StudyÀlex Vila, Estel Pons, Patricia Trinidad García, Daniel Vidal, Sara López, Armand Grau
Clin Investig Arterioscler. 2023;35:272-9
78
Full text access
Open Article
76
Long-term treatment persistence and maintained reduction of LDL-cholesterol levels with evolocumab over 30 months: Results from the Spanish cohort of the European prospective HEYMANS studyAgustín Blanco Echevarría, Juan De Dios García Díaz, Assumpta Caixas, Núria Plana Gil, Miguel Ángel Rico Corral, Ian Bridges, Nafeesa Dhalwani, Sònia Gatell Menchen, Kausik K. Ray
Clin Investig Arterioscler. 2023;35:263-71
76
Full text access
Open Article
67
Evolocumab como tratamiento de la dislipemia secundaria a lorlatinibLaura Pérez Alonso, Raquel Cervera Calero, María Ángeles Campos Fernández de Sevilla, Miguel Ángel Moreno Palanco, Jorge Francisco Gómez Cerezo
Clin Investig Arterioscler. 2023;35:88-90
67
Open Article
55
SmartLab 2.0 in cardiovascular prevention of atherogenic dyslipidemiaRaquel Galván Toribio, Teresa Arrobas Velilla, Cristóbal Morales Porillo, Miguel Ángel Rico, Mar Martínez Quesada, Antonio León Justel
Clin Investig Arterioscler. 2023;35:123-8
55
Open Article
51
Update and validation of the lifetime cardiovascular risk in Spain: IBERLIFERISK2Carlos Brotons, Irene Moral-Peláez, Johanna Vicuña, Cristina Ameixeiras, Carlos Fernández-Lavandera, Miguel Ángel Sánchez-Chaparro
Clin Investig Arterioscler. 2023;35:115-22
51
Open Article